Marek Kirszenbaum

This inventor holds 6 USPTO granted patents, plus 1 CIPO patent and 3 EPO patents. Top assignees: Commissariat a L'energie Atomique Et Aux Energies Alternatives, Institut Pasteur, National Institute for Agricultural Research. Active years: 1994-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Marek Kirszenbaum. Retrieved from https://idiyas.com/inventor/marek-kirszenbaum

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6

% Patents Active = 83.3

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 1)

Average Co-Inventor Count = 4.2

ph-index = 2

Forward Citations = 10(Granted Patents)

Location History:

Jouy-en-Josas, FR (1994)
Orsay, FR (1999 - 2001)
Paris, FR (2003 - 2007)
Vanves, FR (2017)

Company Filing History:

6 out of 8,833

Commissariat a L'energie Atomique Et Aux Energies Alternatives

National Institute for Agricultural Research

patents

where one patent can have more than one assignee

Years Active: 1994-2017

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9623015 - Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a STAT5 antagonist, preferably a thiazolidinedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse (2017-04-18),

2. 7235632 - Isolated mammalian protein present at the surface of all lymphoid progenitor cells and all mature NK cells and uses thereof (2007-06-26),

3. 6528304 - Eukaryotic cells expressing at their surface at least an HLA-G isoform and their applications (2003-03-04),

4. 6291659 - Transcripts of the MHC class I HLA-G gene and their applications (2001-09-18),

5. 5856442 - Transcripts of the MHC class I HLA-G gene and their applications (1999-01-05),

6. 5328827 - Specific DNA molecular probes for Bos-type male genome (1994-07-12),

Title: Marek Kirszenbaum: Innovator in Hematologic Cancer Research

Introduction

Marek Kirszenbaum is a prominent inventor based in Paris, France. He has made significant contributions to the field of cancer research, particularly in the development of innovative treatments for hematologic cancers. With a total of 6 patents to his name, Kirszenbaum's work is paving the way for new therapeutic strategies.

Latest Patents

Kirszenbaum's latest patents include a groundbreaking combination of an anti-cancer agent, such as a tyrosine kinase inhibitor, and a STAT5 antagonist, preferably a thiazolidinedione. This invention aims to eliminate hematologic cancer stem cells in vivo and prevent cancer relapse. The methods involve administering a STAT5 antagonist after an initial course of treatment with an anti-cancer agent to target residual cancer stem cells responsible for relapse. Another notable patent involves an isolated mammalian protein present at the surface of all lymphoid progenitor cells and mature NK cells. This invention details the protein's structure and its potential uses as a marker for these cells, as well as for preparing antibodies directed against the protein.

Career Highlights

Throughout his career, Kirszenbaum has worked with esteemed organizations such as the Commissariat à l'Énergie Atomique et aux Énergies Alternatives and the National Institute for Agricultural Research. His experience in these institutions has greatly contributed to his expertise in cancer research and innovation.

Collaborations

Kirszenbaum has collaborated with notable colleagues, including Edgardo Delfino Carosella and Philippe Moreau. These partnerships have fostered a collaborative environment that enhances the development of innovative solutions in cancer treatment.

Conclusion

Marek Kirszenbaum's contributions to cancer research through his patents and collaborations highlight his role as a leading inventor in the field. His innovative approaches are crucial for advancing treatment options for hematologic cancers.

Profile summary based on public USPTO records.